Engineered Cystine-Knot Peptides that Bind αvβ3 Integrin with Antibody-Like Affinities

Journal of Molecular Biology

Volumn 385, Issue 4, 2009, Pages 1064-1075

  Silverman, Adam P ^a   Levin, Aron M ^a   Lahti, Jennifer L ^a   Cochran, Jennifer R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

cystine knot; integrin; protein engineering; RGD; yeast display

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA2B BETA3 INTEGRIN; ARGININE; ASPARTIC ACID; CYSTINE; GLYCINE; PEPTIDE LIBRARY; PROTEIN DERIVATIVE; SCLEROPROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANTIBODY AFFINITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL ADHESION; CONTROLLED STUDY; CYSTINE KNOT MOTIF; DISULFIDE BOND; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOLECULAR WEIGHT; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN TARGETING;

AGOUTI; PICHIA PASTORIS;

EID: 58149336794     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.11.004     Document Type: Article

References (47)

1. 3 for angiogenesis. Science 264 (1994) 569-571
2. Alghisi G.C., and Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13 (2006) 113-135
3. Pasqualini R., Koivunen E., and Ruoslahti E. αv integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15 (1997) 542-546
4. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032
5. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1992) 11-25
6. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157-1164
7. Curley G.P., Blum H., and Humphries M.J. Integrin antagonists. Cell. Mol. Life Sci. 56 (1999) 427-441
8. Tucker G.C. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8 (2006) 96-103
9. Meyer A., Auernheimer J., Modlinger A., and Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 12 (2006) 2723-2747
10. Plow E.F., Haas T.A., Zhang L., Loftus J., and Smith J.W. Ligand binding to integrins. J. Biol. Chem. 275 (2000) 21785-21788
11. Hautanen A., Gailit J., Mann D.M., and Ruoslahti E. Effects of modification of the RGD sequence and its context on recognition by the fibronectin receptor. J. Biol. Chem. 264 (1989) 1437-1442
12. 3 on platelets and lymphocytes binds to the matrix protein osteopontin. J. Biol. Chem. 272 (1997) 8137-8140
13. 3 selected from random phage display libraries. Biochemistry 34 (1995) 3948-3955
14. Li R., Hoess R.H., Bennett J.S., and DeGrado W.F. Use of phage display to probe the evolution of binding specificity and affinity of integrins. Protein Eng. 16 (2003) 65-72
15. Pfaff M., Tangemann K., Muller B., Gurrath M., Muller G., Kessler H., et al. Selective recognition of cyclic RGD peptide or NMR defined conformation by alpha IIb beta 3, alpha v beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 269 (1994) 20233-20238
16. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R., and Kessler H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 291 (1991) 50-54
17. 1 integrin from phage display library. J. Biol. Chem. 268 (1993) 20205-20210
18. Koivunen E., Wang B., and Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Nat. Biotechnol. 13 (1995) 265-270
19. O'Neil K.T., Hoess R.H., Jackson S.A., Ramachandran N.S., Mousa S.A., and DeGrado W.F. Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins 14 (1992) 509-515
20. Mikecz K. Vitaxin. Curr. Opin. Investig. Drugs 1 (2000) 199-203
21. v integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110 (2004) 326-335
22. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18 (2007) 295-304
23. Kolmar H. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J. 275 (2008) 2684-2690
24. Werle M., Schmitz T., Huang H.L., Wentzel A., Kolmar H., and Bernkop-Schnurch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J. Drug Target. 14 (2006) 137-146
25. Clark R.J., Daly N.L., and Craik D.J. Structural plasticity of the cyclic cystine knot framework: implications for biological activity and drug design. Biochem. J. 394 (2005) 85-93
26. Boder E.T., and Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 (1997) 553-557
27. Colby D.W., Kellogg B.A., Graff C.P., Yeung Y.A., Swers J.S., and Wittrup K.D. Engineering antibody affinity by yeast surface display. Methods Enzymol. 388 (2004) 348-358
28. Chao G., Lau W.L., Hackel B.J., Sazinsky S.L., Lippow S.M., and Wittrup K.D. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1 (2006) 755-768
29. Romanos M. Advances in the use of Pichia pastoris for high-level expression. Curr. Opin. Biotechnol. 6 (1995) 527-533
30. Jackson P.J., McNulty J.C., Yang Y.-K., Thompson D.A., Chai B., Gantz I., et al. Design, pharmacology, and NMR structure of a minimized cystine knot with Agouti-related protein activity. Biochemistry 41 (2002) 7565-7572
31. 18F-FRGD2. J. Nucl. Med. 47 (2006) 113-121
32. 1. J. Cell Biol. 127 (1994) 1129-1137
33. Gan Z.R., Gould R.J., Jacobs P.A., Friedman P.A., and Polokoff M.A. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper Ehis carinatus. J. Biol. Chem. 263 (1988) 19827-19832
34. Jackson P.J., Douglas N.R., Chai B., Binkley J., Sidow A., Barsh G.S., and Millhauser G.L. Structural and molecular evolutionary analysis of Agouti and Agouti-related proteins. Chem. Biol. 13 (2006) 1297-1305
35. Boder E.T., Midelfort K.S., and Wittrup K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl Acad. Sci. USA 97 (2000) 10701-10705
36. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., and Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl Acad. Sci. USA 97 (1999) 5387-5392
37. Cochran J.R., Kim Y.S., Lippow S.M., Rao B., and Wittrup K.D. Improved mutants from directed evolution are biased to orthologous substitutions. PEDS 19 (2006) 245-253
38. Pasqualini R., Koivunen E., and Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 130 (1995) 1189-1196
39. Yamada T., Matsushima M., Inaka K., Ohkubo T., Uyeda A., Maeda T., et al. Structural and functional analysis of the Arg-Gly-Asp sequence introduced into human lysozyme. J. Biol. Chem. 268 (1993) 10588-10592
40. 3. J. Biol. Chem. 270 (1995) 30486-30490
41. Reiss S., Sieber M., Oberle V., Wentzel A., Spangenberg P., Claus R., et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17 (2006) 153-157
42. Hufton S.E., van Neer N., van den Beuken T., Desmet J., Sablon E., and Hoogenboom H.R. Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Lett. 475 (2000) 225-231
43. 3 integrin. J. Mol. Biol. 326 (2003) 1475-1488
44. 3. Science 294 (2001) 339-345
45. 3 in complex with an Arg-Gly-Asp ligand. Science 296 (2002) 151-155
46. Xiao T., Takagi J., Coller B.S., Wang J.-H., and Springer T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432 (2004) 59-67
47. Mardon H.J., and Grant K.E. The role of the ninth and tenth type III domains of human fibronectin in cell adhesion. FEBS Lett. 340 (1994) 197-201